Alexion Pharmaceuticals

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Alexion Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#183 of 15,742 sponsors by registered trial count).

162 total trials 17 currently recruiting 93 completed early-phase tilt top decile by trial count

Alexion Pharmaceuticals: 162 sponsored US clinical trials, 17 recruiting.

Alexion Pharmaceuticals sponsors 162 registered US clinical trials on ClinicalTrials.gov, 17 of them currently recruiting, and 93 completed. 45 of these trials are in Phase 3-4 (later-stage) and 90 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Paroxysmal Nocturnal Hemoglobinuria, with 5 trials.

Top-decile sponsor footprint

Alexion Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#183 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 19/100

93 of 129 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (72.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

162 total, page 1 of 4

RECRUITING Phase 4

A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab

NCT07221838
RECRUITING Phase 2

ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly

NCT07037420
RECRUITING Phase 1

ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy

NCT07218887
RECRUITING Phase 2

Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)

NCT07157787
RECRUITING Phase 1

A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

NCT07081646
RECRUITING Phase 3

Study of Ravulizumab in Pediatric Participants With Primary IgAN

NCT07024563
RECRUITING Phase 3

Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation

NCT06830798
RECRUITING Phase 2

Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation

NCT06744647
RECRUITING

Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

NCT06312644
RECRUITING Phase 3

PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis

NCT06607627
RECRUITING Phase 3

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

NCT06291376
RECRUITING

Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies

NCT05966467
RECRUITING

A Prospective Sub-Study of the Global Hypophosphatasia Registry

NCT05234567
RECRUITING Phase 2

Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD

NCT05346354
RECRUITING

Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)

NCT04202341
RECRUITING

Lysosomal Acid Lipase (LAL) Deficiency Registry

NCT01633489
RECRUITING

Atypical Hemolytic-Uremic Syndrome (aHUS) Registry

NCT01522183
ACTIVE NOT RECRUITING

Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Data

NCT07413250
ACTIVE NOT RECRUITING

Long-term Safety of Danicopan: IPIG Registry-based Cohort Study

NCT07413679
ACTIVE NOT RECRUITING Phase 3

Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP

NCT06079359
ACTIVE NOT RECRUITING Phase 3

Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa

NCT06079372
ACTIVE NOT RECRUITING Phase 3

Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

NCT06183931
ACTIVE NOT RECRUITING Phase 3

Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa

NCT06079281
ACTIVE NOT RECRUITING Phase 3

Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG)

NCT05644561
ACTIVE NOT RECRUITING Phase 3

Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism

NCT05778071
ACTIVE NOT RECRUITING Phase 3

ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE

NCT05746559
ACTIVE NOT RECRUITING Phase 3

Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

NCT05556096
ACTIVE NOT RECRUITING Phase 3

A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH

NCT05389449
ACTIVE NOT RECRUITING

A Study About the Natural History in Adults With BAG3 Dilated Cardiomyopathy (a Type of Heart Disease) (BAG3 DCM)

NCT05981092
ACTIVE NOT RECRUITING

Long-term Follow-up Study of Patients Who Received hLB-001 Gene Therapy

NCT05506254
ACTIVE NOT RECRUITING Phase 3

Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant

NCT04543591
ACTIVE NOT RECRUITING Phase 3

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

NCT04512235
ACTIVE NOT RECRUITING Phase 3

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

NCT04504825
COMPLETED Phase 1

Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine

NCT06071442
TERMINATED Phase 2

Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of ALXN1820 in Adult Participants With Sickle Cell Disease

NCT05565092
COMPLETED Phase 1

Potential Drug Interaction Between ALXN2040 and Rosuvastatin

NCT05708573
COMPLETED Phase 1

Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and Food Effect on ALXN2050 Pharmacokinetics

NCT05578846
TERMINATED Phase 2

Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis

NCT05218096
TERMINATED Phase 1

Study of ALXN2050 in Participants With Hepatic Impairment

NCT05259085
TERMINATED Phase 2

Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

NCT05097989
COMPLETED Phase 1

Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants

NCT05202145
TERMINATED Phase 2

Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis

NCT04999020
COMPLETED Phase 1

Study of ALXN1850 in Participants With Hypophosphatasia (HPP)

NCT04980248
TERMINATED Phase 2

A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

NCT05019521
COMPLETED Phase 1

Study of ALXN2050 in Healthy Adult Participants of Japanese Descent

NCT04952545
COMPLETED Phase 1

Study of ALXN2050 in Participants With Renal Impairment

NCT04623710
TERMINATED Phase 3

Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger

NCT04743804
TERMINATED Phase 2

Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent Surgery

NCT04233073
COMPLETED Phase 1

Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants

NCT04933682
COMPLETED Phase 1

Study to Assess the Effect of Food on a Single Dose of Acoramidis in Healthy Adult Participants

NCT04958135
Page 1 of 4 Next →

Phase Distribution

PhaseTrial count
Phase 1 43
Phase 2 47
Phase 3 42
Phase 4 3

Therapeutic Areas

Paroxysmal Nocturnal Hemoglobinuria 5
Hypophosphatasia 5
Generalized Myasthenia Gravis 4
Healthy 4
Paroxysmal Nocturnal Hemoglobinuria (PNH) 3
Lysosomal Acid Lipase Deficiency 3
HIV Infections 3
PNH 2
AL Amyloidosis 2
gMG 2

What is open in the Alexion Pharmaceuticals pipeline

17 recruiting of 162 indexed (10% open); 93 completed (57%).

Phase mix: 45 late (III/IV) vs 90 early (I/II) (early-phase heavy).

Top condition: Paroxysmal Nocturnal Hemoglobinuria (5 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Alexion Pharmaceuticals: open-pipeline peers nationwide

Peers matched on 162 registered trials and 10% open enrollment, not the therapeutic-area sidebar.

Alexion Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 050100150200 4%6%8%10%12%14% Total trials Recruiting share Alexion PharmaceuticalsUniversity of VermontTemple UniversityTufts UniversityWayne State UniversityVertex Pharmaceuticals IncorporatedBastyr UniversityCorewell Health WestEthicon
Alexion Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Alexion Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 162 trials (± recruiting share)

Sponsors near 10% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Alexion Pharmaceuticals page

162 registered trials is a research-attention snapshot, not an endorsement of Alexion Pharmaceuticals or any single study.

  • 17 of Alexion Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Paroxysmal Nocturnal Hemoglobinuria is the condition Alexion Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Paroxysmal Nocturnal Hemoglobinuria trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Alexion Pharmaceuticals pipeline card: 162 registered trials from official public datasets.Report a data error.